American Society of Hirudotherapy

Host matters: medicinal leech digestive-tract symbionts and their pathogenic potential

Review published in Frontiers in Microbiology (2016)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewSafety & Infection ControlMarden JN et al. · Frontiers in microbiology, 2016

Abstract

Digestive-tract microbiota exert tremendous influence over host health. Host-symbiont model systems are studied to investigate how symbioses are initiated and maintained, as well as to identify host processes affected by resident microbiota. The medicinal leech, Hirudo verbana, is an excellent model to address such questions owing to a microbiome that is consistently dominated by two species, Aeromonas veronii and Mucinivorans hirudinis, both of which are cultivable and have sequenced genomes. This review outlines current knowledge about the dynamics of the H. verbana microbiome. We discuss in depth the factors required for A. veronii colonization and proliferation in the leech crop and summarize the current understanding of interactions between A. veronii and its annelid host. Lastly, we discuss leech usage in modern medicine and highlight how leech-therapy associated infections, often attributable to Aeromonas spp., are of growing clinical concern due in part to an increased prevalence of fluoroquinolone resistant strains.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeReviewJournal Article

Summary

Comprehensive review of leech digestive-tract microbiota, focusing on Aeromonas veronii symbiont and its dual symbiont-pathogen potential in human infections.

Why This Matters for Hirudotherapy

This review summarizes current knowledge of the Hirudo verbana digestive-tract microbiome, which is consistently dominated by two cultivable, genome-sequenced species: Aeromonas veronii and Mucinivorans hirudinis. It discusses factors required for A. veronii colonization and proliferation in the leech crop, host-symbiont interactions, and the growing clinical concern of leech-therapy-associated infections—often attributable to Aeromonas spp.—including the increased prevalence of fluoroquinolone-resistant strains. This review is directly relevant to ASH's domain, as it addresses the microbial safety dimension of hirudotherapy with a medicinal leech species whose usage in modern medicine is noted. As a review, it synthesizes existing literature on symbiont biology and infection risk rather than presenting new experimental data.

Citation

Host matters: medicinal leech digestive-tract symbionts and their pathogenic potential.

Marden JN et al. · Frontiers in microbiology, 2016

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.